Orchid Pharma Limited has reported its financial results for the first quarter of Fiscal Year 2026-27 (Q1 FY27). The company announced a substantial 16% increase in Revenue from Operations, reaching ₹304 crore compared to ₹263 crore in Q1 FY26. Furthermore, EBITDA saw a remarkable surge of 178%, climbing to ₹25 crore from ₹9 crore in the previous year’s corresponding quarter.
Orchid Pharma Announces Q1 FY27 Financial Performance
Orchid Pharma Limited has released its financial results for the first quarter of the fiscal year 2026-27, ending on June 30, 2026. The company highlighted significant growth across key financial metrics.
Key Financial Highlights (Standalone)
The standalone financial performance for Q1 FY27 shows a robust upturn:
- Revenue from Operations for Q1 FY27 stood at ₹304 crore, marking a +16% increase from ₹263 crore in Q1 FY26.
- Other Income decreased by 38% to ₹10 crore in Q1 FY27 from ₹16 crore in Q1 FY26.
- Cost of Goods Sold (COGS) was ₹204 crore in Q1 FY27, up from ₹184 crore in Q1 FY26.
- Employee Expenses were ₹27 crore in Q1 FY27, a slight decrease from ₹28 crore in Q1 FY26.
- Other Expenses remained stable at ₹58 crore in both Q1 FY27 and Q1 FY26.
- EBITDA witnessed a substantial growth of +178%, reaching ₹25 crore in Q1 FY27 compared to ₹9 crore in Q1 FY26.
- Profit After Tax (PAT) turned positive, with the company reporting ₹12 crore in Q1 FY27, a significant improvement from a loss of ₹3 crore in Q1 FY26.
Consolidated Financial Performance
On a consolidated basis, Orchid Pharma also reported positive trends for Q1 FY27:
- Total Income was ₹306.00 crore in Q1 FY27, up from ₹274.76 crore in Q1 FY26.
- Profit/(Loss) Before Exceptional Items & Tax was ₹2.65 crore in Q1 FY27, compared to a loss of ₹6.89 crore in Q1 FY26.
- Profit/(Loss) for the Period was ₹3.22 crore in Q1 FY27, a notable recovery from a loss of ₹5.69 crore in Q1 FY26.
- EPS – Basic & Diluted was ₹0.54 in Q1 FY27, improving from ₹(0.95) in Q1 FY26.
The company’s presentation also detailed its strategic initiatives and integrated platform, emphasizing its position in the anti-infective market.
Source: BSE
